Fox Run Management L.L.C. reduced its stake in Catalent Inc (NASDAQ:CTLT) by 46.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,600 shares of the company’s stock after selling 8,200 shares during the period. Fox Run Management L.L.C.’s holdings in Catalent were worth $383,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Acrospire Investment Management LLC increased its stake in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares during the last quarter. Quantbot Technologies LP increased its stake in Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares during the last quarter. Advisor Group Inc. increased its stake in Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the last quarter. Finally, Legato Capital Management LLC purchased a new position in Catalent in the second quarter valued at approximately $204,000.
Several brokerages have commented on CTLT. Needham & Company LLC reiterated a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price target on the stock in a research note on Thursday, October 26th. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, September 7th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $39.00 price target (up from $30.00) on shares of Catalent in a research note on Thursday, August 31st. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Catalent has a consensus rating of “Buy” and an average price target of $41.67.
In other news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/02/catalent-inc-ctlt-holdings-reduced-by-fox-run-management-l-l-c.html.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The business had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. During the same period in the previous year, the business earned $0.52 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
What are top analysts saying about Catalent Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent Inc and related companies.